Opportunity
Federal Register #FDA-2026-D-7233
HRSA Supplemental Funding for Rural Medical Education and Early Childhood Court Program Support
Buyer
Food and Drug Administration
Posted
September 18, 2026
Respond By
November 17, 2026
Identifier
FDA-2026-D-7233
NAICS
541720, 624410
This opportunity involves supplemental funding from the Health Resources and Services Administration (HRSA) to support rural medical education and early childhood development initiatives. - Government Buyer: - Health Resources and Services Administration (HRSA) - Vendors/Recipients: - University of North Carolina at Chapel Hill - ZERO TO THREE National Center for Infant, Toddler and Families, Inc. - Services Requested: - Technical assistance and resource development for rural graduate medical education programs - Financial and technical support for infant-toddler court sites, including expansion and sustainability activities - Notable Requirements: - Focus on enhancing rural residency planning and development - Expansion of the Infant-Toddler Court approach and support for state award activities - No specific product part numbers or quantities; services are supplemental and programmatic - OEMs: - No Original Equipment Manufacturers (OEMs) are referenced, as this is a funding and technical assistance opportunity - Estimated Contract Value: - University of North Carolina at Chapel Hill: $800,000 - ZERO TO THREE National Center for Infant, Toddler and Families, Inc.: $2,750,000 - Period of Performance: - Awards cover a one-year period within a broader project timeline ending in 2030
Description
The Food and Drug Administration (FDA) is announcing the availability of a draft guidance for industry titled "Target Animal Safety Evaluation for Veterinary Monoclonal Antibody Products." This draft guidance has been developed for veterinary use by the International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products (VICH). It aims to harmonize methods used for the target animal safety evaluation of veterinary monoclonal antibody products and assists in preparing and conducting safety studies under laboratory and field conditions. The guidance is intended to aid in the development of mutually acceptable safety evaluation programs for these products.